Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis

Abstract

Aim Ipragliflozin is a new antidiabetic agent that works through enhancing renal glucose excretion. We aim to synthesize evidence from published randomized controlled trials (RCTs) on the safety and efficacy of ipragliflozin in the management of type 2 diabetes mellitus (T2DM).

Methods We searched PubMed, Scopus, Web of Science, and Cochrane Central register of clinical trials using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager Version 5.3 for windows. Subgroup and sensitivity analyses were conducted.

Results We included 13 RCTs (N=2535 patients) in the final analysis. The overall effect estimates favoured ipragliflozin 50mg monotherapy group over placebo in terms of: HbA1c (Standardized mean difference (SMD)=-1.20%, 95% Confidence interval (95% CI)=[-1.47, -0.93]; p<0.001), fasting plasma glucose (SMD=-1.30 mg/dL, 95% CI [−1.93, −0.67]; p<0.001), fasting serum insulin (SMD=−1.64 μU/mL, 95% CI [−2.70, −0.59]; p=0.002), and body weight (SMD=−0.85 kg, 95% CI [−1.19, −0.51]; p<0.001). Similarly, better glycemic control and significant body weight reduction compared to placebo were attained in ipragliflozin 50 mg combination with metformin, insulin with/without dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone. Ipragliflozin, either alone or in combination, exhibits acceptable safety profile.

Conclusion The presented meta-analysis provides class one evidence that ipragliflozin is safe and effective in the management of T2DM either as monotherapy or an add-on.

Key words

Ipragliflozin - Sodium glucose co-transporter 2 inhibitors - Type 2 diabetes - Meta-analysis

Publikationsverlauf

Eingereicht: 04. Oktober 2017
Eingereicht: 09. Februar 2018

Angenommen: 19. Februar 2018

Artikel online veröffentlicht:
18. Juni 2018

• References

• 1 Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26: 77 LP-82
• 2 American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes Care. 2016; 39 Supplement 1 S52-S59
• 3 Bolen S, Tseng E, Hutfless S et al. Diabetes medications for adults with type 2 diabetes: An update. comparative effectiveness review no. 173. Diabetes Medications for Adults With Type 2 Diabetes: An Update. 2016
• 4 Bennett WL, Maruthur N, Singh S. et al. Comparative effectiveness and safety of medications for type 2 diabetes: An updated systematic review including new drugs and two-drug combinations. Ann Intern Med 2011; 154: 602-613
• 5 Kahn SE, Haffner SM, Heise Ma. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443
• 6 Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2011; 2: 133-145
• 7 Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord 2013; 13: 58
• 8 Vasilakou D, Karagiannis T, Athanasiadou E. et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-274
• 9 Ghosh RK, Bandyopadhyay D, Hajra A. et al. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Int J Cardiol 2016; 212: 29-36
• 10 Wu JHY, Foote C, Blomster J. et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016; 4: 411-419
• 11 United States Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes. FDA News Release 2013
• 12 United States Food and Drug Administration. Press Announcements - FDA approves Jardiance to treat type 2 diabetes. FDA News Release 2014
• 13 United States Food and Drug Administration. Press Announcements - FDA approves Farxiga to treat type 2 diabetes. FDA News Release 2014
• 14 Poole RM, Dungo RT. Ipragliflozin: first global approval. Drugs 2014; 74: 611-617
• 15 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097. doi: 10.1371/journal.pmed.1000097.
• 16 Green S, Higgins PTJ, Alderson P et al. Cochrane Handbook: Cochrane Reviews: Ch 8: Assessing risk of bias in included studies. In: Cochrane Handbook for: Systematic Reviews of Interventions [Internet]. 2011. p. 3–10.
• 17 Altman DG, Bland JM. Standard deviations and standard errors. BMJ 2005; 331: 903
• 18 Fonseca VA, Ferrannini E, Wilding JP. et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 268–273
• 19 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 09/1997; 315: 629-634
• 20 Terrin N, Schmid CH, Lau J. et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003; 22: 2113-2126
• 21 Kashiwagi A, Kazuta K, Takinami Y. et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: The BRIGHTEN study. 2015; 2: 8-18
• 22 Kashiwagi A, Kazuta K, Yoshida S. et al. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2014; 5: 382-391
• 23 Schwartz SL, Akinlade B, Klasen S. et al. Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther 2011; 13: 1219-1227
• 24 Kadokura T, Akiyama N, Kashiwagi A et al. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2014; 106: 50.
• 25 Veltkamp SA, van Dijk J, Collins C. et al. Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther 2012; 34: 1761-1771
• 26 Wilding JPH, Ferrannini E, Fonseca VA. et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study. Diabetes Obes Metab 2013; 15: 403-409
• 27 Lu C-H, Min KW, Chuang L-M. et al. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig. 2016; 7: 366-373
• 28 Kashiwagi A, Kazuta K, Goto K. et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015; 17: 304-308
• 29 Kashiwagi A, Akiyama N, Shiga T. et al. Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: Results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetol Int 2015; 6: 125-138
• 30 Ishihara H, Yamaguchi S, Nakao I. et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): A multi-centre, randomized, placebocontrolled, double-blind study. Diabetes Obes Metab 2016; 18: 1207-1216
• 31 Kashiwagi A, Shiga T, Akiyama N. et al. Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study). Diabetol Int 2015; 6: 104-116
• 32 Kashiwagi A, Takahashi H, Ishikawa H et al. A randomized, double blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment : Results of the LANTERN study (Long-term ASP1941Safety Evaluation in T2DM. 1316094
• 33 Kadokura T, Akiyama N, Kashiwagi A. et al. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus : A randomized, double-blind. Diabetes Res Clin Pract 2014; 106: 50-56
• 34 Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: The persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin 2011; 27: 13-20
• 35 Ohki T, Isogawa A, Toda N. et al. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep. Clin Drug Investig 2016; 36: 313-319
• 36 Yamamoto C, Miyoshi H, Ono K. et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J 2016; 63: 589-596
• 37 Terasaki M, Hiromura M, Mori Y. et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS One 2015; 10: e0143396
• 38 Takakura S, Toyoshi T, Hayashizaki Y. et al. Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Life Sci 2016; 147: 125-131
• 39 Yamada K, Nakayama H, Yoshinobu S. et al. Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. J Diabetes Investig 2015; 6: 699-707
• 40 Iizuka T, Iemitsu K, Takihata M. et al. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study. J Clin Med Res 2016; 8: 116-125
• 41 Tahara A, Takasu T, Yokono M. et al. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016; 130: 159-169
• 42 Smulders RA, Zhang W, Veltkamp SA. et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab 2012; 14: 937-943
• 43 Strojek K, Yoon KH, Hruba V. et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obes Metab 2011; 13: 928-938
• 44 Fonseca VA, Ferrannini E, Wilding JP. et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 268-273
• 45 Baker WL, Smyth LR, Riche DM. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275
• 46 Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses. Diabetes Res Clin Pract. 2014; 105: 313-321
• 47 Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis. 2013 April